Recursion Pharmaceuticals IncNASDAQ:RXRX
- LAST PRICE9.1200
- TODAY'S CHANGE (%)0.2700 (3.0508%)
- Bid / Lots9.0800/ 1
- Ask / Lots9.1200/ 6
- Open / Previous Close8.8800 / 8.8500
- Day Range
- 52 Week Range
- Volume372,344
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RXRX |
|---|---|---|
| 09:32 ET | 160369 | 9.06 |
| 09:34 ET | 46891 | 8.96 |
| 09:36 ET | 81054 | 9.11 |
| 09:38 ET | 26597 | 9.12 |
Today
Jun 8, 2024
DJ Nvidia Owns These 4 Stocks. Here's How They're Doing. -- Barrons.com, from 11:37AM ET on Saturday Jun 08, 2024 by Dow Jones
11:37AM ET on Saturday Jun 08, 2024 by Dow Jones
Jun 3, 2024
Recursion to Participate in Upcoming Investor Conferences, from 9:00AM ET on Monday Jun 03, 2024 by Dow Jones
9:00AM ET on Monday Jun 03, 2024 by Dow Jones
May 29, 2024
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool, from 3:27PM ET on Wednesday May 29, 2024 by Dow Jones
3:27PM ET on Wednesday May 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Recursion Pharmaceuticals Inc | 2.1B | -5.6x | --- |
Janux Therapeutics Inc | 2.1B | -33.4x | --- |
Intellia Therapeutics Inc | 2.3B | -4.8x | --- |
CG Oncology Inc | 2.1B | -27.8x | --- |
Protagonist Therapeutics Inc | 1.9B | 13.2x | --- |
Rocket Pharmaceuticals Inc | 2.0B | -8.0x | --- |
Company Information
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Contact Information
- Headquarters
- 41S Rio Grande StreetSALT LAKE CITY, UT, United States 84101
- Phone
- 385-269-0203
- Fax
- 801-581-7895
Executives
- Independent Chairman of the Board
- Robert Hershberg
- President, Chief Operating Officer
- Tina Larson
- Chief Executive Officer, Director
- Christopher Gibson
- Chief Financial Officer
- Michael Secora
- Director, Chief Research and Development Officer, Chief Commercial Officer
- Najat Khan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
|---|---|
Revenue (TTM) | $46.2M |
Shares Outstanding | 237.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.62 |
Book Value | $1.98 |
P/E Ratio | -5.6x |
Price/Sales (TTM) | 45.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -814.39% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
